Table 2.

Contingency table at the primary end point (week 24) in the placebo group (n=51) and tocilizumab group (n=49) according to the CRP-PMR-AS* represented in the columns and the clin-PMR-AS in the rows

Placebo group Clin-PMR-AS	CRP-PMR-AS	0 to ≤1.5	>1.5 to ≤7	>7 to ≤10	>10 to ≤17	>17	Total
0 to ≤1.5		6	2	0	0	0	8
>1.5 to ≤7		0	18	3	0	0	21
>7 to ≤10		0	0	6	3	0	9
>10 to ≤17		0	0	0	6	0	6
>17		0	0	0	0	6	6
Total		6	20	9	9	6	50

Tocilizumab group Clin-PMR-AS	CRP-PMR-AS	0 to ≤1.5	>1.5 to ≤7	>7 to ≤10	>10 to ≤17	>17	Total
0 to ≤1.5		12	0	0	0	0	12
>1.5 to ≤7		0	19	1	0	0	20
>7 to ≤10		0	0	5	0	0	5
>10 to ≤17		0	0	0	5	0	5
>17		0	0	0	0	5	5
Total		12	19	6	5	5	47

Every cut-off of the CRP-PMR-AS is presented and compared with the clin-PMR-AS results. The number of patients with the same results for both scores are presented in grey.

There was one missing data point for the placebo group and two missing data points for the tocilizumab group.

*Details of the activity scores are provided in the caption of figure 1.

PMR, polymyalgia rheumatica; AS, activity score; CRP, C reactive protein; clin, clinical.